Virologic, Lipid, Renal and Hepatic Laboratory Outcomes After Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Experienced People with HIV: Real-World Evidence from the SHINe-SHIC Cohort
Multicenter retrospective study shows sustained viral suppression and improved lipids in adults with HIV, suggesting doravirine-based regimens provide safe metabolic benefits.
Key Points
To assess 48-week virologic effectiveness and laboratory changes in lipid, renal, and hepatic parameters after switching to doravirine/lamivudine/tenofovir disoproxil fumarate in routine HIV clinical care.
Multicenter retrospective study including 98 treatment-experienced adults with HIV across seven clinical centers in Italy within the SHINe-SHIC network.
Extracted follow-up laboratory outcomes at 24 and 48 weeks post-switch, analyzing viral suppression (primary endpoint: HIV RNA < 50 copies/mL) and secondary metabolic, renal, and liver biomarkers.
At 48 weeks, 88.9% of participants (72/81) achieved HIV RNA < 50 copies/mL and 96.3% (78/81) achieved HIV RNA < 200 copies/mL in observed analysis.
Total cholesterol decreased significantly from 199 to 165 mg/dL (median paired change −22 mg/dL, p < 0.001), LDL cholesterol from 118 to 106.5 mg/dL (−13.5 mg/dL, p = 0.001), and triglycerides from 112.5 to 94 mg/dL (−10.5 mg/dL, p = 0.021).
Serum creatinine and estimated glomerular filtration rate remained stable, while alanine aminotransferase showed a modest increase with no significant changes in aspartate aminotransferase or gamma-glutamyl transferase.